Characteristics of the study group (n = 446; 1990-2008)
| Characteristic . | Value . |
|---|---|
| Age, y | |
| 70-74, n (%) | 249 (56) |
| 75-79, n (%) | 137 (31) |
| ≥ 80, n (%) | 60 (13) |
| Median (range) | 74 (70-88) |
| Performance (ECOG) | |
| 0-1, n (%) | 256 (57) |
| 2, n (%) | 131 (29) |
| 3-4, n (%) | 59 (13) |
| Splenomegaly, n (%) | 46 (10) |
| Lymphadenopathy, n (%) | 38 (9) |
| Karyotype | |
| t(8;21); inversion 16, n (%) | 16 (4) |
| Diploid, n (%) | 173 (39) |
| Chromosome 5 or 7 abnormalities noncomplex, n (%) | 28 (6) |
| Chromosome 5 or 7 abnormalities complex, n (%) | 97 (22) |
| Other noncomplex, n (%) | 79 (18) |
| Other complex, n (%) | 38 (9) |
| Insufficient metaphases, n (%) | 15 (3) |
| Prior malignancy, n (%) | 139 (31) |
| Prior chemotherapy for other malignancies, n (%) | 55 (12) |
| Hemoglobin level | |
| ≤ 8 g/dL, n (%) | 215 (48) |
| 8.1-9.9 g/dL, n (%) | 178 (40) |
| ≥ 10 g/dL, n (%) | 53 (12) |
| Median (range), g/dL | 8.1 (3.0-15.1) |
| WBC count | |
| ≥ 25 × 109/L, n (%) | 142 (32) |
| Median (range), ×109/L | 10.8 (0.4-302) |
| Platelet count | |
| < 100 × 109/L, n (%) | 362 (81) |
| > 400 × 109/L, n (%) | 3 (1) |
| Median (range), ×109/L | 50 (3-808) |
| Marrow blasts | |
| > 50%, n (%) | 218 (49) |
| Median (range), % | 50 (7-98) |
| Lactic dehydrogenase level | |
| > 600, IU/L, n (%) | 322 (72) |
| Median (range), IU/L | 884 (145-58 856) |
| Creatinine level | |
| > 1.3 mg/dL, n (%) | 121 (27) |
| Median (range), mg/dL | 1.1 (0.5-5.1) |
| Bilirubin (mg/dL) | |
| > 1.0 mg/dL, n (%) | 81 (18) |
| Median (range), mg/dL | 0.6 (0.1-4.6) |
| Treatment in the laminar airflow room, n (%) | 333 (75) |
| Antecedent hematologic disease | |
| 0 mo, n (%) | 204 (46) |
| 1-5 mo, n (%) | 117 (26) |
| 6-11 mo, n (%) | 45 (10) |
| ≥ 12 mo, n (%) | 80 (18) |
| Median (range), mo | 1 (0-402) |
| Treatment period | |
| Before 2000 | 271 (61) |
| 2000-2008 | 175 (39) |
| Characteristic . | Value . |
|---|---|
| Age, y | |
| 70-74, n (%) | 249 (56) |
| 75-79, n (%) | 137 (31) |
| ≥ 80, n (%) | 60 (13) |
| Median (range) | 74 (70-88) |
| Performance (ECOG) | |
| 0-1, n (%) | 256 (57) |
| 2, n (%) | 131 (29) |
| 3-4, n (%) | 59 (13) |
| Splenomegaly, n (%) | 46 (10) |
| Lymphadenopathy, n (%) | 38 (9) |
| Karyotype | |
| t(8;21); inversion 16, n (%) | 16 (4) |
| Diploid, n (%) | 173 (39) |
| Chromosome 5 or 7 abnormalities noncomplex, n (%) | 28 (6) |
| Chromosome 5 or 7 abnormalities complex, n (%) | 97 (22) |
| Other noncomplex, n (%) | 79 (18) |
| Other complex, n (%) | 38 (9) |
| Insufficient metaphases, n (%) | 15 (3) |
| Prior malignancy, n (%) | 139 (31) |
| Prior chemotherapy for other malignancies, n (%) | 55 (12) |
| Hemoglobin level | |
| ≤ 8 g/dL, n (%) | 215 (48) |
| 8.1-9.9 g/dL, n (%) | 178 (40) |
| ≥ 10 g/dL, n (%) | 53 (12) |
| Median (range), g/dL | 8.1 (3.0-15.1) |
| WBC count | |
| ≥ 25 × 109/L, n (%) | 142 (32) |
| Median (range), ×109/L | 10.8 (0.4-302) |
| Platelet count | |
| < 100 × 109/L, n (%) | 362 (81) |
| > 400 × 109/L, n (%) | 3 (1) |
| Median (range), ×109/L | 50 (3-808) |
| Marrow blasts | |
| > 50%, n (%) | 218 (49) |
| Median (range), % | 50 (7-98) |
| Lactic dehydrogenase level | |
| > 600, IU/L, n (%) | 322 (72) |
| Median (range), IU/L | 884 (145-58 856) |
| Creatinine level | |
| > 1.3 mg/dL, n (%) | 121 (27) |
| Median (range), mg/dL | 1.1 (0.5-5.1) |
| Bilirubin (mg/dL) | |
| > 1.0 mg/dL, n (%) | 81 (18) |
| Median (range), mg/dL | 0.6 (0.1-4.6) |
| Treatment in the laminar airflow room, n (%) | 333 (75) |
| Antecedent hematologic disease | |
| 0 mo, n (%) | 204 (46) |
| 1-5 mo, n (%) | 117 (26) |
| 6-11 mo, n (%) | 45 (10) |
| ≥ 12 mo, n (%) | 80 (18) |
| Median (range), mo | 1 (0-402) |
| Treatment period | |
| Before 2000 | 271 (61) |
| 2000-2008 | 175 (39) |
ECOG indicates Eastern Cooperative Oncology Group; and WBC, white blood cell.